ArticlePloS one2012
Host defense peptides of thrombin modulate inflammation and coagulation in endotoxin-mediated shock and Pseudomonas aeruginosa sepsis.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 60 citations in OpenAlex.
- A First-In-Human Randomized Controlled Phase 1 Study Assessing the Safety and Tolerability of Topical TCP-25 Gel in Epidermal Suction Blister Wounds.Clinical and translational science · 2026Trial
- The conserved N-terminal histidine in an engineered peptide mediates sepsis treatment efficacy via dual binding to CD14 and LPS.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Rational design of thrombin-derived VFR12 analogs with enhanced antimicrobial, antibiofilm, and anti-inflammatory properties.Scientific reports · 2025Article
- Thrombin-derived C-terminal peptides bind and form aggregates with sulfated glycosaminoglycans.Heliyon · 2024Article
- Applications of peptides in nanosystems for diagnosing and managing bacterial sepsis.Journal of biomedical science · 2024Review
- Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs.Nature communications · 2023Article
- Genome-Wide Identification ofMarine drugs · 2023Article
- Subversion of the Complement System by Pseudomonas aeruginosa.Journal of bacteriology · 2023Review
- RapidBio-protocol · 2022Article
- Differential Internalization of Thrombin-Derived Host Defense Peptides into Monocytes and Macrophages.Journal of innate immunity · 2022Article
- Thrombin-Derived C-Terminal Peptide ReducesAntimicrobial agents and chemotherapy · 2021Article
- Article
- Potent intracellular antibacterial activity of a marine peptide-N6NHApplied microbiology and biotechnology · 2021Article
- Cell-Free DNA Promotes Thrombin Autolysis and Generation of Thrombin-Derived C-Terminal Fragments.Frontiers in immunology · 2021Article
- Concentration- and pH-Dependent Oligomerization of the Thrombin-Derived C-Terminal Peptide TCP-25.Biomolecules · 2020Article
- Thrombin-derived C-terminal fragments aggregate and scavenge bacteria and their proinflammatory products.The Journal of biological chemistry · 2020Article
- Lysocins: Bioengineered Antimicrobials That Deliver Lysins across the Outer Membrane of Gram-Negative Bacteria.Antimicrobial agents and chemotherapy · 2019Article
- Structural basis for endotoxin neutralisation and anti-inflammatory activity of thrombin-derived C-terminal peptides.Nature communications · 2018Article
- TFPI-2 Protects Against Gram-Negative Bacterial Infection.Frontiers in immunology · 2018Article
- Immunohaemostasis: a new view on haemostasis during sepsis.Annals of intensive care · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gram-negative sepsis is accompanied by a disproportionate innate immune response and excessive coagulation mainly induced by endotoxins released from bacteria. Due to rising antibiotic resistance and current lack of other effective treatments there is an urgent need for new therapies. We here present a new treatment concept for sepsis and endotoxin-mediated shock, based on host defense peptides from the C-terminal part of human thrombin, found to have a broad and inhibitory effect on multiple sepsis pathologies. Thus, the peptides abrogate pro-inflammatory cytokine responses to endotoxin in vitro and in vivo. Furthermore, they interfere with coagulation by modulating contact activation and tissue factor-mediated clotting in vitro, leading to normalization of coagulation responses in vivo, a previously unknown function of host defense peptides. In a mouse model of Pseudomonas aeruginosa sepsis, the peptide GKY25, while mediating a modest antimicrobial effect, significantly inhibited the pro-inflammatory response, decreased fibrin deposition and leakage in the lungs, as well as reduced mortality. Taken together, the capacity of such thrombin-derived peptides to simultaneously modulate bacterial levels, pro-inflammatory responses, and coagulation, renders them attractive therapeutic candidates for the treatment of invasive infections and sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.